Can peptides repair teeth or help gum disease?

The short answer

A few peptide-based dental products are real and in use: a self-assembling peptide (P11-4) that helps repair early enamel decay, an enamel-matrix protein gel (Emdogain) used in gum surgery, and casein-phosphopeptide pastes (CPP-ACP, sold as MI Paste or Tooth Mousse) for remineralization. None of them regrows a tooth, and the evidence is moderate at best. The injectable "research" peptides people ask about for teeth and gums — BPC-157, TB-500, GHK-Cu, KPV — have only animal or cell data in dentistry. On GLP-1 drugs, the dental issues worth knowing are dry mouth, acid exposure from reflux or vomiting, and telling your dentist before any sedation.

Evidence tier: Tier 1–2 for CPP-ACP, Emdogain and P11-4 (systematic reviews and RCTs, with mixed results); Tier 2–4 for antimicrobial peptides; Tier 4 for BPC-157, TB-500, GHK-Cu and KPV in dentistry. This is education, not medical or dental advice.

The key points:

• P11-4 helps early, non-cavitated lesions — mostly alongside fluoride; it does not fill a cavity
• Emdogain is an FDA-approved gum-regeneration product — modest extra attachment gain in surgery
• CPP-ACP beats placebo but isn't clearly better than fluoride
• Anti-cavity peptides (C16G2, histatins) reached Phase 2 trials, with no approved product
• BPC-157 and friends for gums — rat and cell studies only
• GLP-1s — a weak dry-mouth signal, plausible erosion from reflux, and a sedation precaution

Peptides that are actually used in dentistry

Evidence tier: 1–2 — systematic reviews and randomized trials, with heterogeneous results.

P11-4 (Curodont Repair). P11-4 is a short synthetic peptide that self-assembles into a scaffold inside early enamel lesions, where minerals from saliva can redeposit. In the best-known randomized trial, children with active early lesions on molars did better with P11-4 plus fluoride varnish than with varnish alone at 3 and 6 months, with no adverse events (Alkilzy 2018). Systematic reviews are less enthusiastic: a 2023 network meta-analysis ranked P11-4 with fluoride highly among white-spot treatments (Xie 2023), while another 2023 meta-analysis judged half its trials at high risk of bias and was "uncertain" about the benefit (EAPD 2023). The fair summary: a reasonable option for early, non-cavitated lesions, best as an add-on to fluoride, with short follow-up and many small single-center trials.

Emdogain (enamel matrix derivative). Emdogain is a gel of enamel-matrix proteins (amelogenins, from pigs) applied during periodontal surgery to help regenerate the tissues that hold a tooth. It is FDA-approved as a device. A Cochrane review found about 1.1 mm more clinical attachment gain and 0.9 mm more pocket reduction at one year compared with surgery alone, with high variability between trials and no difference in tooth loss (Esposito 2009). It is a protein mixture used by periodontists, not a peptide you'd buy or inject.

CPP-ACP (MI Paste, Tooth Mousse). Casein phosphopeptide–amorphous calcium phosphate uses milk-derived phosphopeptides to keep calcium and phosphate available at the tooth surface. Reviews find it better than placebo over the long term but not clearly better than fluoride, and evidence for adding it on top of fluoride is insufficient (2014 systematic review; 2019 meta-analysis). People with a milk-protein allergy should avoid it.

Anti-cavity and antimicrobial peptides

Evidence tier: 2–4 — Phase 2 trials and lab work, no approved products.

The idea of a peptide that kills cavity-causing bacteria without wiping out the rest of the mouth is appealing, and it got as far as human trials. C16G2, a peptide targeted at Streptococcus mutans, reduced S. mutans, lactic acid and demineralization in an early rinse study (Sullivan 2011), and several Phase 2 trials of gels, rinses and varnishes were completed between 2014 and 2018 — but no Phase 3 trial or approved product followed. Histatin-derived P-113 modestly reduced gum bleeding in Phase 2 gingivitis trials and was well tolerated (Phase 2 trial, 2002), again without a product. LL-37, the human antimicrobial peptide, is studied in periodontitis mainly through lab and animal work (2025 review); see our LL-37 guide.

BPC-157, TB-500, GHK-Cu and KPV for teeth and gums

Evidence tier: 4 — animal and cell studies only.

Community posts often suggest injectable peptides for gum disease, dental implants or healing after extractions. The dental evidence is thin. BPC-157 reduced inflammation in a rat model of periodontitis (Keremi 2009); there are no dental trials in people. TB-500 (thymosin β4) has been studied in periodontal-ligament cells in the lab (2016). We found no dental studies for GHK-Cu or KPV.

FDA lists BPC-157, TB-500, injectable GHK-Cu and KPV among bulk substances that may present significant safety risks in compounding, and says it has not identified human exposure data for KPV (FDA). Rat data on gum inflammation is a reason for research, not a reason to inject an unregulated product near your jaw. Periodontal disease has effective, proven treatments — deep cleaning, local antimicrobials, surgery — that a peptide should not replace. See our sourcing and safety guide.

GLP-1 drugs and your teeth

Evidence tier: 3–4 — case reports, adverse-event signals and one large records study.

"Ozempic teeth" is a social-media phrase, not a finding — we found no peer-reviewed study measuring tooth damage from GLP-1 drugs. What does exist:

• Dry mouth. A three-patient case series described severe dry mouth on semaglutide that improved after stopping or treating it (Mawardi 2023), and an analysis of FDA adverse-event reports found a dry-mouth signal specific to semaglutide (2026). Saliva protects enamel, so persistent dry mouth is worth raising with your dentist.
• Acid exposure. The same analysis found vomiting, regurgitation and reflux signals across GLP-1 drugs. Repeated stomach acid in the mouth can erode enamel; that's plausible but not yet measured in GLP-1 users. After vomiting, rinse with water and wait before brushing. See GLP-1 nausea management.
• Gums. The signal may even run the other way: a large retrospective study linked tirzepatide to lower periodontitis risk than other GLP-1 drugs (2026), and reviews note weight loss and better blood sugar can help gum health (2025 review). Retrospective data can't prove cause.

Dental sedation while on a GLP-1

Evidence tier: 3 plus professional guidance.

The most practical point in this article: tell your dentist you're on a GLP-1 before any sedation or general anesthesia. GLP-1s slow stomach emptying, and in one study 56% of GLP-1 users had residual stomach contents on ultrasound before anesthesia versus 19% of non-users (Sen 2024) — which raises the risk of inhaling stomach contents under sedation. Anesthesia guidance has changed: the 2023 ASA advice to hold doses before procedures (ASA) was followed by 2024 multisociety guidance (2024) that moved toward individual risk assessment. Don't stop or adjust your dose on your own; your dentist, anesthesia provider and prescriber decide together. Routine cleanings and fillings without sedation aren't affected. See the GLP-1 complete guide.

What to do with this

1. Early white spots or enamel decay: ask your dentist about fluoride first, and whether P11-4 or CPP-ACP adds anything for you.
2. Gum disease: get proven periodontal treatment; Emdogain is something a periodontist may use during surgery.
3. On a GLP-1: mention it at every dental visit, flag dry mouth, protect enamel after reflux or vomiting, and always disclose it before sedation.
4. Injectable research peptides for teeth or gums: there's no human dental evidence and FDA has flagged them — don't use them in place of dental care.

Related on this site

• GLP-1 nausea: why it happens and how to manage it
• LL-37: the human antimicrobial peptide
• KPV: mechanism and evidence
• BPC-157
• GLP-1 complete guide
• Peptide safety and sourcing guide
• Our evidence-tier framework

References

• Alkilzy et al. 2018. Self-assembling peptide P11-4 for early enamel caries (randomized trial). J Dent Res. PMID 28892645
• Xie et al. 2023. Network meta-analysis of white spot lesion therapies. BMC Oral Health. PMID 37264364
• Self-assembling peptides for white spot lesions: systematic review and meta-analysis. 2023. Eur Arch Paediatr Dent. PMID 37702901
• Esposito et al. 2009. Enamel matrix derivative (Emdogain) for periodontal tissue regeneration. Cochrane Database Syst Rev. PMID 19821315
• Long-term effects of CPP-ACP: systematic review. 2014. J Dent. PMID 24705069
• CPP-ACP versus fluorides: meta-analysis. 2019. Oral Health Prev Dent. PMID 31825022
• Sullivan et al. 2011. C16G2 rinse and S. mutans. Caries Res. PMID 21860239
• P-113 histatin gel in gingivitis. 2002. J Clin Periodontol. PMID 12492903
• LL-37 in periodontitis: review. 2025. Int Immunopharmacol. PMID 39954662
• Keremi et al. 2009. BPC 157 in rat periodontitis. J Physiol Pharmacol. PMID 20388954
• Thymosin β4 in periodontal ligament cells. 2016. PLoS One. PMID 26789270
• Mawardi et al. 2023. Semaglutide-associated hyposalivation: case series. Medicine (Baltimore). PMID 38206684
• Oral adverse events of GLP-1 receptor agonists in FAERS. 2026. JDR Clin Trans Res. PMID 42935458
• Tirzepatide versus GLP-1 RAs and oral outcomes. 2026. Diabetes Res Clin Pract. PMID 42764072
• GLP-1 receptor agonists and periodontal health: review. 2025. J Periodontal Res. PMID 40348599
• Sen et al. 2024. GLP-1 RA use and residual gastric content before anesthesia. JAMA Surg. PMID 38446466
• Multisociety clinical practice guidance on GLP-1 RAs in the perioperative period. 2024. Surg Obes Relat Dis. PMID 39482213
• FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. fda.gov

Limitations

This is educational content, not medical or dental advice. Dental peptide trials are mostly small with short follow-up, research-peptide evidence in dentistry is animal-only, and GLP-1 oral-health data are early signals.

• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.